Aquinox Pharmaceuticals, Inc. (AQXP) Given Consensus Recommendation of “Hold” by Analysts
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has been given a consensus rating of “Hold” by the seven analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $24.67.
A number of equities research analysts have commented on the stock. BidaskClub raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Canaccord Genuity set a $22.00 price objective on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, ValuEngine raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd.
Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in Aquinox Pharmaceuticals by 10.0% during the 1st quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after purchasing an additional 11,035 shares during the period. Archon Partners LLC lifted its position in Aquinox Pharmaceuticals by 44.0% during the 2nd quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after purchasing an additional 5,500 shares during the period. Investment Centers of America Inc. acquired a new position in Aquinox Pharmaceuticals during the 1st quarter valued at about $172,000. Alps Advisors Inc. lifted its position in Aquinox Pharmaceuticals by 4.7% during the 2nd quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after purchasing an additional 939 shares during the period. Finally, Nexthera Capital LP acquired a new position in Aquinox Pharmaceuticals during the 2nd quarter valued at about $1,276,000. Institutional investors own 95.15% of the company’s stock.
Aquinox Pharmaceuticals (AQXP) traded down 9.19% during mid-day trading on Friday, hitting $12.85. 230,748 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $14.28 and a 200 day moving average of $14.77. The stock’s market capitalization is $301.51 million. Aquinox Pharmaceuticals has a 52 week low of $9.83 and a 52 week high of $19.97.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, hitting analysts’ consensus estimates of ($0.59). Equities analysts forecast that Aquinox Pharmaceuticals will post ($2.15) earnings per share for the current fiscal year.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.